CAR T cells for T-cell leukemias: insights from mathematical models
From MaRDI portal
Publication:2656040
Abstract: Immunotherapy has the potential to change the way all cancer types are treated and cured. Cancer immunotherapies use elements of the patient immune system to attack tumor cells. One of the most successful types of immunotherapy is CAR-T cells. This treatment works by extracting patient's T-cells and adding to them an antigen receptor allowing tumor cells to be recognized and targeted. These new cells are called CAR-T cells and are re-infused back into the patient after expansion in-vitro. This approach has been successfully used to treat B-cell malignancies (B-cell leukemias and lymphomas). However, its application to the treatment of T-cell leukemias faces several problems. One of these is fratricide, since the CAR-T cells target both tumor and other CAR-T cells. This leads to nonlinear dynamical phenomena amenable to mathematical modeling. In this paper we construct a mathematical model describing the competition of CAR-T, tumor and normal T-cells and studied some basic properties of the model and its practical implications. Specifically, we found that the model reproduced the observed difficulties for in-vitro expansion of the therapeutic cells found in the laboratory. The mathematical model predicted that CAR-T cell expansion in the patient would be possible due to the initial presence of a large number of targets. We also show that, in the context of our mathematical approach, CAR-T cells could control tumor growth but not eradicate the disease.
Recommendations
- CAR T cell therapy in B-cell acute lymphoblastic leukaemia: insights from mathematical models
- Optimal CAR T-cell immunotherapy strategies for a leukemia treatment model
- Cellular immunotherapy for high grade gliomas: mathematical analysis deriving efficacious infusion rates based on patient requirements
- Modeling CAR T-cell therapy with patient preconditioning
- A mathematical model for chemoimmunotherapy of chronic lymphocytic leukemia
Cites work
Cited in
(16)- Mathematical models of leukaemia and its treatment: a review
- CAR T cell therapy in B-cell acute lymphoblastic leukaemia: insights from mathematical models
- Modeling CAR T-cell therapy with patient preconditioning
- A fully-decoupled discontinuous Galerkin approximation of the Cahn–Hilliard–Brinkman–Ohta–Kawasaki tumor growth model
- On the analysis of a mathematical model of CAR-T cell therapy for glioblastoma: insights from a mathematical model
- The effect of chemotaxis on T-cell regulatory dynamics
- An optimal treatment strategy for a leukemia immune model governed by reaction-diffusion equations
- A Mathematical Model of TCR-T Cell Therapy for Cervical Cancer
- Understanding the role of B cells in car T-cell therapy in leukemia through a mathematical model
- Car T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma
- A comparative study for mathematical modelling of the contest of CAR-T and tumour cells in solid cancers using fractional- and integer-order derivatives
- Mathematical modeling of leukemia chemotherapy in bone marrow
- Mathematical model of CAR T-cell therapy for a B-cell lymphoma lymph node
- A mathematical model to the melanoma dynamics involving car T-cells
- A posteriori error-driven space-time adaptive FEM for accurate avascular tumor and drug interaction modeling
- Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer
This page was built for publication: CAR T cells for T-cell leukemias: insights from mathematical models
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2656040)
